“Nobody Was Armed At NCI”: US FDA Head Sharpless Adjusts To Life As Regulator
Executive Summary
Acting commissioner is entering the usual learning curve for new leaders of the agency. It’s a reminder of how unusual it was to skip that step under his predecessor.
You may also be interested in...
Acting Normal: US FDA's Unusual Interim Period Drags On
The messaging around the US FDA commissioner transition has emphasized continuity and business-as-usual. But this is still all pretty weird.
Sharpless Calls For A Nimble, Flexible, More Efficient US FDA
In his first speech to an outside group, Sharpless strikes a collaborative tone, saying he expects to listen to the advice of the FDA bar, as well as his own experts.
External Collaboration At US FDA Is More Difficult Than At NIH, Sharpless Says
Acting US FDA commissioner Norman Sharpless outlines some key differences between his new position and his former role at the NCI.